Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia

Seggewiss, 2010, Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update, Blood, 115, 3861, 10.1182/blood-2009-12-234096 Childs, 2004, Nonmyeloablative allogeneic immunotherapy for solid tumors, Annu Rev Med, 55, 459, 10.1146/annurev.med.55.091902.104511 Reddy, 2003, Immunobiology of acute graft-versus-host disease, Blood Rev, 17, 187, 10.1016/S0268-960X(03)00009-2 Hodi, 2007, Cytotoxic T-lymphocyte-associated antigen-4, Clin Cancer Res, 13, 5238, 10.1158/1078-0432.CCR-07-0813 Magistrelli, 1999, A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells, Eur J Immunol, 29, 3596, 10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y Ueda, 2003, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease, Nature, 423, 506, 10.1038/nature01621 Kavvoura, 2007, Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis, J Clin Endocrinol Metab, 92, 3162, 10.1210/jc.2007-0147 Oaks, 2000, Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease, J Immunol, 164, 5015, 10.4049/jimmunol.164.10.5015 Wang, 2002, Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence, J Neuroimmunol, 130, 224, 10.1016/S0165-5728(02)00228-X Liu, 2003, Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus, Scand J Immunol, 57, 568, 10.1046/j.1365-3083.2003.01232.x Wong, 2005, Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus, Rheumatology, 44, 989, 10.1093/rheumatology/keh663 Sato, 2004, Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis, Rheumatology (Oxford), 43, 1261, 10.1093/rheumatology/keh303 Toussirot, 2009, Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity, Arthritis Res Ther, 11, R101, 10.1186/ar2747 Read, 2006, Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo, J Immunol, 177, 4376, 10.4049/jimmunol.177.7.4376 Roncarolo, 2007, Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans, Nat Rev Immunol, 7, 585, 10.1038/nri2138 Pérez-García, 2007, CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors, Blood, 110, 461, 10.1182/blood-2007-01-069781 Azarian, 2007, Donor CTLA-4 +49 A/G*GG genotype is associated with chronic GVHD after HLA-identical haematopoietic stem-cell transplantations, Blood, 110, 4623, 10.1182/blood-2007-08-106385 Wu, 2009, Functional polymorphism of CTLA-4 and ICOS genes in allogeneic hematopoietic stem cell transplantation, Clin Chim Acta, 403, 229, 10.1016/j.cca.2009.03.037 Piccioli, 2010, CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence, Ann Hematol, 89, 613, 10.1007/s00277-009-0885-5 Sellami, 2010, Effect of donor CTLA-4 alleles and haplotypes on graft-versus-host disease occurrence in Tunisian patients receiving a human leukocyte antigen-identical sibling hematopoietic stem cell transplant, Hum Immunol, 72, 139, 10.1016/j.humimm.2010.11.008 Thomas, 1975, Bone-marrow transplantation (second of two parts), N Engl J Med, 292, 895, 10.1056/NEJM197504242921706 Scrucca, 2007, Competing risk analysis using R: an easy guide for clinicians, Bone Marrow Transplant, 40, 381, 10.1038/sj.bmt.1705727 Excoffier, 2005, Arlequin ver. 3.0: An integrated software package for population genetics data analysis, Evol Bioinform Online, 1, 47, 10.1177/117693430500100003 Edinger, 2003, CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation, Nat Med, 9, 1144, 10.1038/nm915 Hoffmann, 2002, Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation, J Exp Med, 196, 389, 10.1084/jem.20020399 Coombes, 2005, Regulatory T cells and intestinal homeostasis, Immunol Rev, 204, 184, 10.1111/j.0105-2896.2005.00250.x